YU14102A - Mezoprogestini (progesteron receptor modulatori) kao komponente kompozicija za terapiju zamene hormona (hrt) - Google Patents
Mezoprogestini (progesteron receptor modulatori) kao komponente kompozicija za terapiju zamene hormona (hrt)Info
- Publication number
- YU14102A YU14102A YU14102A YUP14102A YU14102A YU 14102 A YU14102 A YU 14102A YU 14102 A YU14102 A YU 14102A YU P14102 A YUP14102 A YU P14102A YU 14102 A YU14102 A YU 14102A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- hrt
- mesoprogestins
- component
- replacement therapy
- progesterone receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Ovaj pronalazak se odnosi na upotrebu mezoprogestina za proizvodnju farmaceutskih sredstava za žensku kontracepciju, kao i na farmaceutske preparate za žensku kontracepciju i na postuapk kontracepcije kod žena davanjem efikasne količine mezoprogesita u ženskom kontraceptivnom sredstvu. Opciono mezoprogestin može da se upotrebi u kombinaciji sa estrogenom, Mezoprogestini su definisani kao jedinjenja koja poseduju i agonistične i antagonistične aktivnosti na progesteron receptor (PR) in vivo. Oni stabilizuju funkciju PR-a na srednjem nivou agonista i anagonista. Odgovarajuća funkcionalna stanja ne mogu da se ostvare progestinima ili antiprogestinima. J867, J912, J956 i J1042 su mezoprogestini poželjni prema ovom pronalasku.[The present invention refers to the use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as component for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods of treating hormone deficiency and hormone irregularity symptoms. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38614099A | 1999-08-31 | 1999-08-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU14102A true YU14102A (sh) | 2006-01-16 |
| RS50396B RS50396B (sr) | 2009-12-31 |
Family
ID=23524333
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1605924B1 (sh) |
| JP (1) | JP2003513908A (sh) |
| KR (1) | KR100729311B1 (sh) |
| CN (1) | CN1454088A (sh) |
| AR (1) | AR025456A1 (sh) |
| AT (1) | ATE413168T1 (sh) |
| AU (1) | AU781836B2 (sh) |
| BG (1) | BG65846B1 (sh) |
| BR (1) | BR0013710A (sh) |
| CA (1) | CA2383659C (sh) |
| CO (1) | CO5200773A1 (sh) |
| CZ (1) | CZ301412B6 (sh) |
| DE (1) | DE60040764D1 (sh) |
| EA (1) | EA007840B1 (sh) |
| EE (1) | EE200200102A (sh) |
| ES (1) | ES2316402T3 (sh) |
| HR (1) | HRP20020266A2 (sh) |
| HU (1) | HUP0202460A3 (sh) |
| IL (2) | IL148417A0 (sh) |
| LT (1) | LT5011B (sh) |
| LV (1) | LV12942B (sh) |
| MX (1) | MXPA02002190A (sh) |
| NO (1) | NO20021000L (sh) |
| NZ (1) | NZ517469A (sh) |
| PE (1) | PE20010581A1 (sh) |
| PL (1) | PL198798B1 (sh) |
| RO (1) | RO122180B1 (sh) |
| RS (1) | RS50396B (sh) |
| SI (1) | SI20851B (sh) |
| SK (1) | SK287121B6 (sh) |
| UA (1) | UA75339C2 (sh) |
| WO (1) | WO2001034126A2 (sh) |
| ZA (1) | ZA200201621B (sh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| DE50304970D1 (de) * | 2002-08-02 | 2006-10-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
| US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| RU2611370C1 (ru) * | 2016-01-12 | 2017-02-21 | Общество с ограниченной ответственностью Медицинская Корпорация "РАНА" | Применение препарата Лаеннек для уменьшения или устранения проявления менопаузальных симптомов (варианты) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2054271A (en) | 1932-05-17 | 1936-09-15 | Schering Kahlbaum Ag | Production of crystallized hormone esters |
| DE699310C (de) | 1936-11-20 | 1940-11-27 | Chemische Ind Ges | Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols |
| US2225419A (en) | 1937-03-01 | 1940-12-17 | Schering Corp | Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols |
| US2611773A (en) | 1951-08-21 | 1952-09-23 | Upjohn Co | Estradiol 17-cyclopenetanepropionate |
| US2990414A (en) | 1957-03-26 | 1961-06-27 | Syntex Sa | 17-undecenoate of estradiol |
| US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| MX9301121A (es) * | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| DE4225623C2 (de) * | 1992-08-03 | 1994-06-30 | Karl Hehl | Verfahren zur Herstellung einer pulverförmigen Spritzgußmasse für die Herstellung von Porzellan und deren Verwendung |
| US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5391557A (en) * | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
| SK283662B6 (sk) * | 1994-10-24 | 2003-11-04 | Schering Aktiengesellschaft | Kompetetívne progesterónantagonisty na kontrolu samičej fertility zameranú podľa potreby |
| DE19610635A1 (de) * | 1996-03-11 | 1997-09-18 | Schering Ag | Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie |
| JP2000514785A (ja) * | 1996-06-25 | 2000-11-07 | アクゾ・ノベル・エヌ・ベー | プロゲストゲン―抗プロゲストゲン処方 |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| EP1144396A2 (en) * | 1999-01-14 | 2001-10-17 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
-
2000
- 2000-08-31 UA UA2002032428A patent/UA75339C2/uk unknown
- 2000-08-31 EP EP00991840A patent/EP1605924B1/en not_active Expired - Lifetime
- 2000-08-31 CA CA002383659A patent/CA2383659C/en not_active Expired - Lifetime
- 2000-08-31 HU HU0202460A patent/HUP0202460A3/hu unknown
- 2000-08-31 RO ROA200200230A patent/RO122180B1/ro unknown
- 2000-08-31 BR BR0013710-3A patent/BR0013710A/pt not_active Application Discontinuation
- 2000-08-31 CN CN00812257A patent/CN1454088A/zh active Pending
- 2000-08-31 DE DE60040764T patent/DE60040764D1/de not_active Expired - Lifetime
- 2000-08-31 PL PL353931A patent/PL198798B1/pl not_active IP Right Cessation
- 2000-08-31 PE PE2000000892A patent/PE20010581A1/es not_active Application Discontinuation
- 2000-08-31 NZ NZ517469A patent/NZ517469A/en unknown
- 2000-08-31 CZ CZ20020706A patent/CZ301412B6/cs not_active IP Right Cessation
- 2000-08-31 JP JP2001536126A patent/JP2003513908A/ja active Pending
- 2000-08-31 AU AU36332/01A patent/AU781836B2/en not_active Ceased
- 2000-08-31 IL IL14841700A patent/IL148417A0/xx unknown
- 2000-08-31 EE EEP200200102A patent/EE200200102A/xx unknown
- 2000-08-31 KR KR1020027002815A patent/KR100729311B1/ko not_active IP Right Cessation
- 2000-08-31 CO CO00065516A patent/CO5200773A1/es not_active Application Discontinuation
- 2000-08-31 RS YUP-141/02A patent/RS50396B/sr unknown
- 2000-08-31 EA EA200200285A patent/EA007840B1/ru not_active IP Right Cessation
- 2000-08-31 ES ES00991840T patent/ES2316402T3/es not_active Expired - Lifetime
- 2000-08-31 WO PCT/US2000/023771 patent/WO2001034126A2/en active IP Right Grant
- 2000-08-31 SI SI200020041A patent/SI20851B/sl not_active IP Right Cessation
- 2000-08-31 AT AT00991840T patent/ATE413168T1/de not_active IP Right Cessation
- 2000-08-31 AR ARP000104537A patent/AR025456A1/es unknown
- 2000-08-31 SK SK297-2002A patent/SK287121B6/sk not_active IP Right Cessation
-
2002
- 2002-02-26 BG BG106443A patent/BG65846B1/bg unknown
- 2002-02-26 ZA ZA200201621A patent/ZA200201621B/en unknown
- 2002-02-27 IL IL148417A patent/IL148417A/en not_active IP Right Cessation
- 2002-02-28 NO NO20021000A patent/NO20021000L/no not_active Application Discontinuation
- 2002-02-28 MX MXPA02002190A patent/MXPA02002190A/es active IP Right Grant
- 2002-03-27 LT LT2002037A patent/LT5011B/lt not_active IP Right Cessation
- 2002-03-28 HR HR20020266A patent/HRP20020266A2/hr not_active Application Discontinuation
- 2002-03-28 LV LVP-02-54A patent/LV12942B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200607798A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
| WO2006135638A3 (en) | Tanaproget compositions containing ethinyl estradiol | |
| CA2412161A1 (en) | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | |
| WO2000007979A3 (en) | Compounds and compositions for delivering active agents | |
| MXPA03007837A (es) | Composiciones para suministrar bisfosfonatos. | |
| WO2002092102A3 (en) | Treatment of conditions relating to hormone deficiencies by administration of progestins | |
| WO2006015259A3 (en) | Compounds and compositions as modulators of steroid hormone nuclear receptors | |
| WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
| WO2006053172A3 (en) | The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases | |
| AU2002364082A1 (en) | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function | |
| WO2006066011A3 (en) | Compounds and compositions as modulators of steroidal receptors and calcium channel activities | |
| UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
| WO1999063976A3 (en) | Liver-selective glucocorticoid antagonist for treating diabetes | |
| EP1637132A4 (en) | EXTERNAL PREPARATION FOR TREATING THE FEET OF AN ATHLETE | |
| BG105761A (en) | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | |
| WO2004096118A3 (en) | Composition for improving cognition and memory | |
| YU14102A (sh) | Mezoprogestini (progesteron receptor modulatori) kao komponente kompozicija za terapiju zamene hormona (hrt) | |
| YU13902A (sh) | Mezoprogestini (progesteron receptor modulatori) kao komponente kontraceptivnih sredstava za žene | |
| MXPA04008221A (es) | Composiciones de espuma de alginato. | |
| EA200601089A1 (ru) | Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение | |
| YU14002A (sh) | Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja | |
| PT1635843E (pt) | Terapia de substituição hormonal e de depressão compreendendo dienogest | |
| WO2003084521A3 (en) | Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy | |
| WO2005046666A8 (de) | Pharmazeutische zusammensetzung zur behandlung der stressinkontinenz und/oder mischinkontinenz | |
| IL125983A0 (en) | Pharmaceutical composition comprising factor xiiia |